- Home
- GILD vs TJX Comparison
GILD vs TJX Comparison
Compare GILD & TJX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | TJX |
|---|---|---|
| Founded | 1987 | 1962 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4B | 177.3B |
| IPO Year | 2001 | 1994 |
Fundamental Metrics
Financial Performance| Metric | GILD | TJX |
|---|---|---|
| Price | $139.94 | $162.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 16 |
| Target Price | $146.50 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 4.9M | 3.5M |
| Earning Date | 04-23-2026 | 05-20-2026 |
| Dividend Yield | ★ 2.34% | 1.19% |
| EPS Growth | ★ 1684.21 | 14.32 |
| EPS | ★ 6.78 | 4.87 |
| Revenue | $24,689,000,000.00 | ★ $29,078,407,000.00 |
| Revenue This Year | $4.65 | $6.75 |
| Revenue Next Year | $5.96 | $5.81 |
| P/E Ratio | ★ $20.66 | $33.21 |
| Revenue Growth | ★ 9.98 | 6.04 |
| 52 Week Low | $95.30 | $119.75 |
| 52 Week High | $157.29 | $162.68 |
Technical Indicators
Market Signals| Indicator | GILD | TJX |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 59.85 |
| Support Level | $108.90 | $152.69 |
| Resistance Level | $149.38 | $162.63 |
| Average True Range (ATR) | 3.30 | 2.84 |
| MACD | 0.04 | 0.54 |
| Stochastic Oscillator | 48.48 | 93.72 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About TJX TJX Companies Inc. (The)
Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2025, the company generated roughly $56 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.